![William Fairey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Fairey
Direktor/Vorstandsmitglied bei
MIRUM PHARMACEUTICALS, INC.
Vermögen: 767 116 $ am 30.06.2026
Profil
William C.
Fairey is Executive Chairman at Respira Therapeutics, Inc. since 2022.
He serves as Independent Director at Rein Therapeutics, Inc. starting in 2023, at Ascendis Pharma A since 2022, and at Mirum Pharmaceuticals, Inc. since 2021.
He is also Director at Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. Formerly, Mr. Fairey was Director at Lung Therapeutics LLC from 2021 to 2023, Independent Director at KalVista Pharmaceuticals, Inc. from 2024 to 2026, Chief Operating Officer & Executive Vice President at ChemoCentryx, Inc. from 2018 to 2019, Chief Commercial Officer & Executive VP at MyoKardia, Inc. from 2019 to 2020, Vice President-Sales & Management Markets at Actelion Pharmaceuticals US, Inc. from 2001 to 2003, President at Actelion Pharmaceuticals US, Inc. from 2013 to 2017, Regional Vice President at Australia Asia Pacific Hotels Ltd., President at Actelion Pharmaceuticals Canada, Inc. from 2003 to 2008, and Regional Vice President-Australia Asia Pacific at Actelion Pharmaceuticals Ltd. from 2008 to 2013.
Education includes an MBA from St. Mary's College of California conferred in 1994 and an undergraduate degree from the University of Oregon conferred in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ASCENDIS PHARMA A/S -.--% | 18.03.2026 | 2’117 ( -.--% ) | 474 441 $ | 31.05.2026 |
| 15.06.2026 | 2’500 ( 0% ) | 292 675 $ | 30.06.2026 | |
| 13.05.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von William Fairey
| Unternehmen | Position | Beginn |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 19.08.2021 |
| ASCENDIS PHARMA A/S | Direktor/Vorstandsmitglied | 01.09.2022 |
| REIN THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 31.10.2023 |
Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. | Direktor/Vorstandsmitglied | - |
Respira Therapeutics, Inc.
 Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Focuses on pulmonary delivery of therapeutics for respiratory diseases | Vorsitzender | 01.01.2022 |
Ehemalige bekannte Positionen von William Fairey
| Unternehmen | Position | Ende |
|---|---|---|
| KALVISTA PHARMA | Direktor/Vorstandsmitglied | 11.06.2026 |
Lung Therapeutics LLC
 Lung Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel pipeline of first-in-class medicines for fibrosis | Direktor/Vorstandsmitglied | 31.10.2023 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01.11.2020 |
| CHEMOCENTRYX, INC. | Geschäftsführer | 18.01.2019 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von William Fairey
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule therapeutics for inflammatory, autoimmune diseases and cancer | Health Technology |
Rein Therapeutics, Inc.
 Rein Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops stapled peptide drugs | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of cardiovascular diseases | Health Technology |
Lung Therapeutics LLC
Lung Therapeutics LLC BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel pipeline of first-in-class medicines for fibrosis | Health Technology |
St. Mary's College of California
 St. Mary's College of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Health Technology |
Australia Asia Pacific Hotels Ltd.
 Australia Asia Pacific Hotels Ltd. Hotels/Resorts/Cruise linesConsumer Services Operates hotels | Consumer Services |
Respira Therapeutics, Inc.
Respira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Focuses on pulmonary delivery of therapeutics for respiratory diseases | Health Technology |
Actelion Pharmaceuticals Canada, Inc. | |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets small molecule protease inhibitors for diseases | Health Technology |
Actelion Pharmaceuticals Ltd.
 Actelion Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and distributes molecular weight drugs | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd. |
Wählen Sie MarketScreener 
